이차 진행성 다발성 경화증 환자를 대상으로 한 오렐라부티닙 연구
비활성 2차 진행형 다발성 경화증 환자에서 오렐라브루티닙과 위약의 효능 및 안전성을 비교하는 3상 무작위 이중 맹검 연구
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Patient and Medical Information
- 전화번호: 833-269-4696
- 이메일: clinicaltrialsinfo@zenasbio.com
연구 연락처 백업
- 이름: Patient and Medical Information
- 전화번호: 833-269-4696
- 이메일: clinialtrialsinfo@zenasbio.com
연구 장소
-
-
-
Tbilisi, 그루지야, 0114
- 모병
- LTD Pineo Medical Ecosystem
-
Tbilisi, 그루지야, 0186
- 모병
- Raymann, LLC
-
Tbilisi, 그루지야, 0159
- 모병
- NNLE Jo Ann University Hospital
-
Tbilisi, 그루지야, 0186
- 모병
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi, K'alak'i T'bilisi, 그루지야, 0114
- 모병
- JSC Curatio
-
-
Saburtalo
-
Tbilisi, Saburtalo, 그루지야, 0160
- 모병
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
Athens
-
Cholargós, Athens, 그리스, 15562
- 모병
- Metropolitan General Hospital
-
-
Attica
-
Athens, Attica, 그리스, 11526
- 모병
- Errikos Dunant Hospital
-
-
-
-
Hesse
-
Bad Homburg, Hesse, 독일, 61348
- 모병
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
Constanța County
-
Constanța, Constanța County, 루마니아, 900123
- 모병
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti, Suceava, 루마니아, 725400
- 모병
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
Kauno
-
Kaunas, Kauno, 리투아니아, 50161
- 모병
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
Arizona
-
Phoenix, Arizona, 미국, 85032
- 모병
- Arizona Neuroscience Research, LLC
-
Scottsdale, Arizona, 미국, 85253
- 모병
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton, California, 미국, 92835
- 모병
- Fullerton Neurology and Headache Center
-
Torrance, California, 미국, 90502-2006
- 모병
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood, California, 미국, 90048
- 모병
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton, Florida, 미국, 33487
- 모병
- SFM Clinical Research, LLC
-
Bradenton, Florida, 미국, 34209
- 모병
- Nova Clinical Research, LLC
-
Clearwater, Florida, 미국, 33761
- 모병
- MS and Neuromuscular Center of Excellence
-
Maitland, Florida, 미국, 32751
- 모병
- Neurology Associates
-
Naples, Florida, 미국, 34105
- 모병
- Aqualane Clinical Research
-
Tampa, Florida, 미국, 33612
- 모병
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46256
- 모병
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Medical Center
-
Roeland Park, Kansas, 미국, 66205
- 모병
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02131
- 빼는
- Boston Clinical Trials
-
Worcester, Massachusetts, 미국, 01655
- 모병
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills, Michigan, 미국, 48307
- 모병
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87131
- 모병
- University Of New Mexico School Of Medicine
-
-
New York
-
New York, New York, 미국, 10029
- 모병
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus, Ohio, 미국, 43235
- 모병
- The Boster Center for Multiple Sclerosis
-
Columbus, Ohio, 미국, 43221
- 모병
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville, South Carolina, 미국, 29605
- 모병
- Premier Neurology
-
-
Tennessee
-
Cordova, Tennessee, 미국, 38018
- 모병
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio, Texas, 미국, 78258
- 모병
- Lone Star Neurology
-
Sherman, Texas, 미국, 75092
- 모병
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
-
Sovet, 벨기에, 1408
- 모병
- DCC Neoclinic - Sofia
-
-
Limburg
-
Overpelt, Limburg, 벨기에, 3900
- 모병
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Pleven, 불가리아, 5800
- 모병
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv, Plovdiv, 불가리아, 4000
- 모병
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia, Sofia, 불가리아, 1680
- 모병
- Diagnostic and Consultative Center Convex
-
Sofia, Sofia, 불가리아, 1510
- 모병
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo, Tarnovo, 불가리아, 5000
- 모병
- Medical Center Medica Plus OOD
-
-
-
-
-
Kragujevac, 세르비아, 34000
- 모병
- University Clinical Centre of Kragujevac
-
Niš, 세르비아, 18000
- 모병
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade, Belgrade, 세르비아, 11000
- 모병
- University Clinical Centre of Serbia
-
-
-
-
A Coruña
-
A Coruña, A Coruña, 스페인, 15006
- 모병
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo, Galicia, 스페인, 36312
- 모병
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid, Madrid, 스페인, 28007
- 모병
- Hospital Gregorio Marañon
-
Majadahonda, Madrid, 스페인, 28222
- 모병
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga, Málaga, 스페인, 29016
- 모병
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta, Seville, 스페인, 41950
- 모병
- Hospital Vithas Nisa Sevilla
-
-
-
-
Harju
-
Tallinn, Harju, 에스토니아, 10617
- 모병
- Astra clinic (Clinic4U)
-
-
-
-
-
Ivano-Frankivsk, 우크라이나, 76943
- 모병
- Neuro Global
-
Lviv, 우크라이나, 79010
- 모병
- Lviv National Medical University named after Danylo Galytskiy
-
Vinnytsia, 우크라이나, 21009
- 모병
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi, Chernivtsi Oblast, 우크라이나, 58023
- 모병
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, 우크라이나, 76018
- 모병
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, 우크라이나, 79000
- 모병
- Limited Liability Company Medical Center Neuroclinic
-
Lviv, Lviv Oblast, 우크라이나, 79029
- 모병
- Limited Liability Company "Neurofocus"
-
-
-
-
Chieti
-
Chieti, Chieti, 이탈리아, 66100
- 모병
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli, Isernia/Molise, 이탈리아, 86077
- 모병
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
-
Choceň, 체코, 56501
- 모병
- NEUROHK, s.r.o.
-
Jihlava, 체코, 58601
- 모병
- Regional Hospital Jihlava
-
-
-
-
-
Zagreb, 크로아티아, 10 000
- 모병
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
-
Lublin, 폴란드, 20-064
- 모병
- Galen Clinic
-
Plewiska, 폴란드, 62-064
- 모병
- Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
-
Poznan, 폴란드, 15-540
- 모병
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin, 폴란드, 70-111
- 모병
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory, 폴란드, 44-240
- 모병
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-605
- 모병
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, 폴란드, 20-601
- 모병
- Malva Trials
-
Lublin, Lublin Voivodeship, 폴란드, 20-064
- 모병
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin, Lublin Voivodeship, 폴란드, 20-064
- 모병
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól, Lubusz Voivodeship, 폴란드, 67-100
- 모병
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw, Mazovian, 폴란드, 02-172
- 모병
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów, Rzeszów, 폴란드, 35-323
- 모병
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, 폴란드, 40-081
- 모병
- Centrum Medyczne Pratia Katowice
-
Katowice, Silesian Voivodeship, 폴란드, 40-571
- 모병
- MA-LEK Clinical Sp. z o.o.
-
Katowice, Silesian Voivodeship, 폴란드, 40-584
- 모병
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice, Upper Silesia, 폴란드, 40-686
- 모병
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan, Wielkopolska, 폴란드, 61-853
- 모병
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan, Wielkopolska, 폴란드, 60-324
- 모병
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, 폴란드, 91-743
- 모병
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz, Łódź Voivodeship, 폴란드, 90-324
- 모병
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo, 푸에르토 리코, 00969
- 모병
- Caribbean Center for Clinical Research
-
-
-
-
Brest
-
Pordic, Brest, 프랑스, 29609
- 모병
- CHU Brest Hospital Cavale
-
-
Gard
-
Nîmes, Gard, 프랑스, 30029
- 모병
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
Yveline
-
Poissy, Yveline, 프랑스, 78300
- 모병
- Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
-
-
-
-
-
Budapest, 헝가리, 1145
- 모병
- National Institute of Clinical Neurosciences
-
Tatabánya, 헝가리, 2800
- 모병
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom, Komarom-Esztergom Vamegye, 헝가리, 2500
- 모병
- Valeomed Kft.
-
-
-
-
New South Wales
-
Kogarah, New South Wales, 호주, 2217
- 모병
- Southern Neurology Suite 2
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
위약 비교기: Placebo Group
Placebo PO daily |
Placebo orally |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
기간: Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
12 Week CDP
기간: Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
기간: Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
기간: Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
기간: Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
기간: Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
기간: Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
기간: Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
기간: Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
기간: Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
기간: Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ZB020-03-002
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .